Are There Differences Between Women and Men After a Percutaneous Intervention?

Prior research has shown that women with coronary artery disease who undergo percutaneous revascularization present more comorbidities, require less aggressive treatments, have greater long-term morbidity rates and worst functional status and/or post-procedure angina.

This study used data from the CPORT-E trial (Cardiovascular Patient Outcomes Research Team Non primary Percutaneous Coronary Intervention) to assess baseline differences between sexes at 6 weeks and 9 months after the procedure.

The primary endpoint (PEP) was overall mortality at 6 weeks, while the secondary endpoint (SEP) was a composite of all-cause mortality, type Q acute myocardial infarction, and culprit vessel revascularization at 9 months.

Out of the 18,867 assessed patients, 6851 were women (36%). The women were older, more frequently of African-American origin, and had higher rates of hypertension, diabetes, heart failure, previous stroke, or peripheral vascular disease. In contrast, they had lower rates of prior angioplasty or myocardial revascularization surgery, prior myocardial infarction, and smoking.

In coronary angiography, women had more findings of single-vessel disease, and less frequently received multivessel angioplasty.

Read also: IVUS in Femoropopliteal PCI: Should We Start Using It?

While there were no differences between the PEP and the SEP, women had higher rates of bleeding, vascular repair, and repeat diagnostic catheterization. 

Significant differences were also observed in health status (measured by a Self-Assessment Questionnaire); they presented worse health status at 6 weeks and at 9 months at the expense of higher frequency of angina, worse quality of life, and physical limitations.

Conclusion

Being female was a predictor of worse health status at 6 weeks and at 9 months after angioplasty.

Dr. Andrés Rodríguez.
Member of the Editorial Board, SOLACI.org

Original Title: Sex Differences in Health Status and Clinical Outcomes After Nonprimary Percutaneous Coronary Intervention.

Reference: Pranoti G. Hiremath et al. Circ Cardiovasc Interv. 2022;15:e011308.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....